Top Markets
#1 ORDI ORDI +105.28%
#2 pippin pippin +48.89%
#3 tomiNet tomiNet +42.76%
#4 SATS (Ordinals) SATS (Ordinals) +41.44%
#5 1000SATS (Ordinals) 1000SATS (Ordinals) +40.63%
#6 Axelar Axelar +28.30%
#7 Bio Protocol Bio Protocol +27.90%
#8 Swarms Swarms +26.30%
#9 Drift Protocol Drift Protocol +25.62%
#10 MemeCore MemeCore +24.82%
Coin of the day
ORDI ORDI
Setări
Limbă
ROMâNă
Monedă
USD
Temă
Neovacs S.A. Neovacs S.A.

Neovacs S.A.

ALNEV
Rang în acțiuni #21228
Neovacs S.A., a biotechnology company, focuses on the development of... Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Preț acțiune
$0.00047446
Capitalizare de piață
$82.80
Schimbare (1 zi)
0.00%
Schimbare (1 an)
-98.16%
Țară
FR
Tranzacționează Neovacs S.A. (ALNEV)

Categorie

Healthcare
Raport P/B pentru Neovacs S.A. (ALNEV)
Raport P/B la data de April 2026 TTM: 0.00
Conform celor mai recente rapoarte financiare și prețului acțiunilor Neovacs S.A., raportul P/B actual (TTM) este 0.00. La sfârșitul anului 2023, compania avea un P/B de 16.05.
Istoricul raportului P/B pentru Neovacs S.A. din 2007 până în 2026
Raport P/B la sfârșitul fiecărui an
An Raport P/B Schimbă
2026 (TTM) 0.00 -100.00%
2024 9.86 -38.60%
2023 16.05 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 0.00%
2012 0.00 0.00%
2011 0.00 0.00%
2010 0.00 0.00%
2009 0.00 0.00%
2008 0.00 0.00%
2007 0.00 0.00%
Raport P/B pentru companii similare sau competitoare
Companie Raport P/B Diferență raport P/B Țara
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 5.6367 -
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.0433 -
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 2.4872 -
US
UCB SA UCB SA
UCB SA
UCB.BR
 4.7311 -
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.9706 -
NL